The anti-tumoral effects of different local anesthetics on human endometrial carcinoma cell line: An in-vitro study

Erel Varlik K.1, Yenisey Cigdem2
1Department of Anaesthesiology, Medical Faculty, Adnan Menderes University, Aydin, Turkey
2Department of Clinic Biochemistry, Medical Faculty, Adnan Menderes University, Aydin, Turkey

Abstract

Background: There is accumulating evidence on the inhibitory effect of local anesthetic agents on metastasis and tumor recurrence on various cancer types. In this study, we aimed to test the effects of lidocaine, bupivicaine and prilocaine on cellular viability and apoptosis on human endometrial adenocarcinoma cell lines (Ishikawa cells).

Material and methods: Human Endometrial adenocarcinoma cells (Ishikawa cells) were exposed to different concentrations of local anesthetic agents for 24, 48, and 72 hours. The cell viability assay was performed via MTT and concentrations corresponding to 50% effective concentration (EC50) of cells were determined for each agent. Apoptosis was evaluated via commercial Biocolor ApoPercentage assay.

Results: All of the three local anesthetics reduced the amount of viable tumor cells in a dose-dependent manner. The EC50 values (mM) at 24, 48 and 72 h incubation periods were 11.67, 1.915, 2.114 for lidocaine 11.4, 5.21, 3.12 for bupivacaine 7.64 mM, 7.3 mM, and 2.83 mM, for prilocaine respectively.

Conclusion: Lidocaine, bupivacaine, and prilocaine have anti-tumoral effects on Ishikawa cell lines. All of the tested agents induced apoptosis and necrosis at high concentrations in a dose dependent-manner.

Key words: lidocaine, bupivacaine, prilocaine, Ishikawa cell lines, local anesthetics, cancer surgery, metastasis

Introduction

Local anesthetics (LA) are commonly used in procedures requiring general, regional and local anesthesia for the interventional and surgical treatment of cancer. There are many other pharmacological effects of LA in addition to the analgesic and antiarrhythmic effects of local anesthetics [1,2]. Retrospective studies have demonstrated that the use of certain anesthetic agents may reduce the risk of metastasis, cancer recurrence and overall survival at the postoperative period [3-6]. Local anesthetics such as lidocaine might exert beneficial effects in the treatment of cancer by inhibition of cell proliferation, invasion, and migration which are essential in angiogenesis and tumor metastasis [7-9]. Commonly employed local anesthetics including bupivacaine and prilocaine have also been shown to trigger apoptosis in a variety of tumor cells [10-12]. Therefore, apoptosis is suggested to play an important role in the local anesthetic-induced cell toxicity in tumor cells [12-14].
In this study, we aimed to investigate the anti-tumoral effects of lidocaine, bupivacaine and prilocaine in human endometrial cancer cells (Ishikawa cells). To our knowledge, this is the first study to investigate the anti-tumoral effects of these agents on Ishikawa cells. We hypothesized that these local anesthetic agents might induce apoptosis and reduce the viability of Ishikawa cells in vitro.

**Material and methods**

**Reagents**

Commercially available lidocaine (L1026), bupivacaine (606189) and prilocaine (P2939000) were obtained from Sigma-Aldrich. Different concentrations of LAs were prepared using serum-free medium. All of the solutions were prepared immediately prior to use. For cell viability and apoptosis, the analysis concentrations were chosen as clinically achievable plasma levels.

**Cell Culture**

Ishikawa cell lines were established an endometrial adenocarcinoma. The cells induced well differentiated adenocarcinoma in athymic nude mice. Estrogen and progesterone receptors were demonstrated both in cell culture and in induced tumours and taken from Adnan Menderes University Science and Technology Center (BİLTEM) cell line stocks. Cells were maintained in phenol red Dulbecco’s Modified Eagle’s Medium: nutrient mixture F12 (DMEM/F12, Lonza, Belgium) and supplemented with 10% fetal bovine serum (PAA, France), 2 mM of L-glutamine (Lonza, Belgium), penicillin (100 U/mL), and streptomycin (100 μg/m) (Lonza, Belgium), 1% Non-Essentials amino acids (Sigma-Aldrich). Ishikawa cells were cultured at 37°C in a CO2 atmosphere (5%) and maintained in monolayer culture. Experiments were performed when cells reached ~80-90% confluence.

**Measurement of Cell Viability**

Cell viability was assayed via commercial MTT Cell Viability Kit (Biotium, 3159 Corporate Place, Hayward, CA 94545, Cat No: 30006). The antiproliferative and cytotoxic effects of lidocaine, bupivacaine and prilocaine in human endometrial adenocarcinoma cells were assessed using commercial MTT assay (Biotium Co., 3159 Corporate Place, Hayward CA 94545, USA. Catalog Number: 30006). Briefly, Ishikawa cells were seeded in 96 well plates (10000 cells per well) in 100 μL growth medium. 24 hours after seeding, we aspirated the growth medium, added 100 μl fresh serum-free DMEM/F12 including 1, 10, 20, 30, 50 mM lidocaine, 0.02, 2, 12, 14, 17 mM bupivacaine and 2, 12, 50, 60, 80 mM prilocaine. After treated with LAs for 24, 48 and 72 hours, the medium was aspirated and fresh 10 μL MTT solutions (ready in commercial kit) in 90 μL serum-free DMEM/F12 medium was added into each well, and cells were incubated for 4h at 37°C at 5% CO2 incubator. Finally, the MTT containing medium was removed and 200 μL DMSO (dimethyl sulfoxide) was added per well to dissolve the formazan crystals and wells were incubated on a shaker for 10-15 minutes. The optical density (OD) was measured using BIOTEK LX 800 at wave length 570 nm. The percentage of viability was calculated using the probit method of Miller and Tainter.

**Statistical analysis**

All experiments were performed at least for triple times. IBM SPSS Statistics 25 software was used for statistical analysis. Shapiro Wilk test was implemented to check normality assumption. Statistical analysis was performed by using nonparametric Mann Whitney U Test, since the variables did not show a normal distribution. Hypothesis tests were performed as two-sided at α=0.05 significance level. The median 50% effective concentration (EC50) values for three agents were calculated using the probit method of Miller and Tainter.

**Results**

Effects of Lidocaine, Bupivacaine, and Prilocaine on Cell Viability

The viability of Ishikawa cells was determined after incubation with lidocaine, bupivacaine prilocaine and at serially diluted concentrations for 24, 48 and 72 hours. Lidocaine, bupivacaine and prilocaine were inhibited the growth of Ishikawa cells in a dose- and time-dependent manner (Figure 1; p<0.001). The percentages of cell death (calculated for 24, 48, and 72 hours) were given in Table 1.

![Figure 1 - Effects of lidocaine, bupivacaine, and prilocaine on endometrial cancer cell viability in different time zone.](image)

**Apoptosis assay**

Ishikawa cells which treated in different doses of LAs were used for apoptosis assay. Commercial Biocolor ApoPercentage kit (Biocolor; www.biocolor.co.uk) were used. Cells were seeded in 96 well plates (30.000 cell per well) in 200 μl culture medium. After 24 hours incubation period, at 37°C/5% CO2 until confluence was reached (~80-90 %) incubation medium was removed and cells were rinsed in fresh medium. Then, LAs were added into each well in culture medium at 1/10/20/30/50 mM lidocaine, 0.02/2/12/14/17 mM bupivacaine and 2/12/50/60/80 mM prilocaine concentrations. The Ishikawa cell including only growth medium was used as control. After 24, 48 and 72h incubation period, the medium was aspirated from the cells to preserve floating cells. 100 μl/well fresh culture medium containing 5 μl APOPercentage Dye and the agents were added into the wells, 30 minutes prior to incubation. After incubating the plates for the 30 more minutes, we decanted the culture medium/dye mixture, and gently washed the cells twice with 200 μl/well using DPBS. As soon as the wells were washed, the plates were visualized under inverted microscope and photographs were taken. For colorimetric determination after thoroughly washing the cells, 100 μl/well APOPercentage Dye release reagent were added and the plates were shaked gently for 10 min, then the absorbance was measured via BIOTEK LX 800 at 550 nm.
Figure 2 - Effects of local anesthetics on the growth of endometrial cancer cells. Cell viability was determined by MTT assays in Ishikawa cell lines treated with lidocaine, bupivacaine, and prilocaine for 24, 48 and 72 hours. All values are expressed mean±SD (ANOVA; p<0.0001 and Kruskal-Wallis Test; p<0.0001).

Table 1: The cell viability values of lidocaine, bupivacaine and prilocaine (Mean±SD)

|     | Lidocaine (mM) |     |     | Bupivacaine (mM) |     |     | Prilocaine (mM) |
|-----|----------------|-----|-----|-----------------|-----|-----|----------------|
|     | 24 h           | 48 h| 72 h| 24 h            | 48 h| 72 h| 24 h           |
| 1   | 88.76±7.81     | 81.15±10.14 | 92.49±2.62 | 105.16±12.27     | 70.11±15.72 | 83.04±14.25 |
| 10  | 71.28±23.81    | 15.31±4.66  | 10.65±0.40  | 96.88±5.23       | 50.9±11.86  | 57.48±1.56   |
| 20  | 19.1±0.72      | 10.48±0.09  | 6.33±0.34   | 36.07±2.1        | 12.48±2.39  | 5.3±1.52    |
| 30  | 18.51±0.76     | 7.37±0.51   | 4.94±0.24   | 18.39±0.62       | 4.06±0.16   | 2.45±0.11   |
| 50  | 16.62±1.38     | 7.12±0.54   | 4.49±0.27   | 18.01±0.67       | 4.28±0.22   | 2.37±0.03   |
|     |                |              |              | 2                  | 10            | 50             | 60             | 80             |
| 2   | 95.64±13.74    | 80.03±17.06 | 90.9±4.0    | 95.99±5.23       | 10.89±1.03   | 10.12±0.63 |
| 12  | 36.99±5.23     | 10.89±1.03  | 10.12±0.63  | 17.53±4.41       | 10.06±2.06   | 7.25±0.58  |
| 60  | 17.04±2.88     | 3.96±0.24   | 2.59±0.47   | 16.99±1.07       | 3.87±0.19   | 2.47±0.06  |
| 80  | 16.99±1.07     | 3.87±0.19   | 2.47±0.06   |                   |              |                |                |
The EC50 values of lidocaine for 24, 48, and 72 hours were found as 11.67 mM, 1.92 mM, and 2.11 mM, respectively. The EC50 values of bupivacaine for 24, 48, and 72 hours were found as 11.4 mM, 5.21 mM, and 7.3 mM, respectively. The EC50 values of prilocaine for 24, 48, and 72 hours were found as 7.64 mM, 7.3 mM, and 2.83 mM, respectively (Figure 2). After 10 mM doses, lidocaine significantly inhibited cell viability in Ishikawa cell lines according to dose and time dependent manner. After 20 mM doses at 48 and 72 hours, approximately no cells were seen in the wells. Also, bupivacaine killed almost all of the cells and there seemed no cells at 14 and 17 mM, which was the lowest value as compared with lidocaine. Also, prilocaine began to inhibit Ishikawa cell at 12 mM concentration and at the highest concentrations approximately, there were no cells. Compared to EC50 values of three compounds, we saw that at 24 hours prilocaine had the lowest value. At 48 hours, lidocaine had the lowest EC50 value, and 72 hours lidocaine and prilocaine both of them had lower values as compared to bupivacaine.

**Induction of apoptosis**

The quantitative APO Percentage assay, which measured the earliest stages of apoptosis, also showed induction of apoptosis in response to 48 hours of treatment with lidocaine, bupivacaine, and prilocaine. As seen in Figure 3, lidocaine triggered apoptosis at the lowest concentrations which is 1 mM and the highest concentrations (50 mM) approximately all cells were undergoing necrosis. Whilst, bupivacaine was effectively apoptotic at higher concentration (14 mM), as the same for lidocaine, the highest dose (17 mM), most of the cells underwent necrosis instead of apoptosis. Because of prilocaine also has similar powerful apoptotic effects as lidocaine, at the lowest concentrations (2 mM) almost all cells underwent apoptosis. Increased apoptosis were seen with increasing concentrations in all of three LAs in Ishikawa cell lines. At the highest concentrations, cells underwent necrosis instead of apoptosis. These data support the results that we got from cell viability assay.

*Figure 3* - Apoptosis induced by local anaesthetics in endometrial cancer cells. As seen in figure at higher doses cells were gone necrosis instead as apoptosis which is supporting cell viability assay.
Discussion

In the study, it is important that all three local anesthetics show inhibitory effect on Ishikawa cells even at the lowest doses. Moreover, all three substances inhibited the viability of more than 50% in the cells at 24th, 48th, and 72nd hours at average of 10 mM concentration. All of substances led apoptosis in cancer cells even the lowest doses. Futhermore almost no more cells also were left when used at high doses.

Surgical resection of solid tumors can be curative, but surgery merely triggers stress responses which can induce immunosuppression. Furthermore inadvertent seeding of cancer cells may also occur during the operation. These factors may increase the risk of tumor metastasis in the perioperative period.

Although there are in-vitro studies on the mechanism of action of local anesthetics in cancer cell biology in recent years, knowledge on potential mechanisms is still limited [15]. Lidocaine is one of the most widely used local anesthetics and it effectively inhibits the invasiveness of cancer cells as in vitro in the concentrations used in surgical procedures [16]. Bupivacaine as well as lidocaine has also been shown to induce apoptosis of breast tumor cells at clinically used concentrations [14]. Prilocaine has been reported to exhibit apoptotic activity via transcriptional regulation mechanisms of specific protein or protein synthesis in osteoblastic cells [11]. Therefore apoptosis-inducing activity of local anesthetics may provide additional benefits for their use that could have substantial clinical implications in cancer surgery.

Lidocaine suppresses the growth of non-small cell lung cancer (NSCLC) in a dose- and time dependent manner [17]. The ED50 (effective dose) value of lidocaine was found as 9.51 and 6.14 mM for A549 and HS20 cells (both cells were different types of non-small cell lung cancer cells) at 24h, respectively. The total percentage of apoptosis (including early and late apoptosis) was significantly increased in the lidocaine treated group [17]. The ED50 value of lidocaine for A549 was close to our EC50 value of lidocaine at 24th h.

Lidocaine and bupivacaine inhibit the growth of both breast tumor cell lines in a dose- and time-dependent manner [14]. The authors [14] have showed that ED50 values of lidocaine and bupivacaine were significantly lower in MCF-7 cells than in MCF-10A cells. For MCF-7 cells, the ED50 of lidocaine was 4.50±0.26 mM and that of bupivacaine was 1.30±0.11 mM at 24 hours. The ED50 value of lidocaine and bupivacaine at 24 h in the study for MCF cells are much lower than our results in Ishikawa cells. Chang et al. [14] found the mean percentages of MCF-7 (human breast adenocarcinoma) cells, which were apoptotic after treatment with lidocaine (7.4 mM) or bupivacaine (2.6 mM), were 74% and 81%, respectively. However, in nontumorigenic cell line MCF-10A (human mammary epithelial cell lines) treatment with lidocaine (7.4 mM) or bupivacaine (2.6 mM) resulted in apoptosis of 8% and 19% of the cells, respectively (p<0.001). They suggested that their results were in consistent with their cell viability data indicating that lidocaine and bupivacaine exhibit higher cytotoxicties in MCF-7 than in MCF-10A cells.

Chang et al. [18] demonstrated the direct effect of lidocaine and bupivacaine inhibiting cell growth and colony formation of thyroid cancer cells. Kawasaki et al. [19] showed that lidocaine suppressed neutrophil function, inhibited ATP synthesis, reduced mitochondrial membrane potential, and induced apoptosis.

The mechanisms of cell toxicity from local anesthetics have not been fully elucidated. In U937 histiocytic lymphoma cells, lidocaine induced apoptosis at concentrations below 12 mM and induced necrosis at concentrations above 15 mM [20]. We also found that at the beginning concentrations from 10 mM in 48 hours lidocaine was lethal for endometrial cancer cells. Moreover, at 30 mM and 50 mM concentrations almost there was no cells in the well during cell viability assay. Concurrently, we couldn’t take any photograph above 20 mM, because of there was no cells in the wells. Our findings supported the research of Kamiya et al.20 Similar observations have been reported by others [13,21,22]. Accumulating evidence suggests that local anesthetics can cause rapid neuronal death through triggering apoptosis and necrosis [21, 22]. Lee et al. [23] show that local anesthetics induce human renal cell apoptotic signaling by caspase activation and via inhibition of pro-survival signaling pathways. However, Hirata et al. [24] demonstrate that lidocaine directly inhibits tyrosine kinase activity of EGFR and suppresses the corneal epithelial cell proliferation.

In conclusion, we demonstrated that lidocaine, bupivacaine and prilocaine significantly inhibited growth of Ishikawa cell lines. Lidocaine and prilocaine were found to exert prominent apoptotic effect at lowest concentrations, but bupivacaine induced its apoptosis at higher concentrations on Ishikawa cells. The present study showed that lidocaine, bupivacaine, and prilocaine inhibits cellular growth and triggers apoptosis in Ishikawa cell lines for the first time. We also observed that LA have higher toxicity on Ishikawa cells in a dose dependent manner and the tumor cells have undergone almost complete necrosis at high doses. In the present study, we demonstrated for the first time the direct inhibitory effect of local anesthetics on Ishikawa cell lines.

There are some limitations of our study which should be considered while interpreting our results. Firstly; we have not compared the effects of the local anesthetic agents on cultured healthy endometrial cell lines. Secondly; our study has been conducted in-vitro conditions therefore in-vivo studies are necessary in order to determine the effect of these agents on endometrial cancer cells in clinical conditions.

As a result, this study has shown that three commonly used local anesthetic drugs (lidocaine, bupivakiane, prilocaine) have anti-tumoral effects on Ishikawa cells in-vitro. However, further experimental and clinical research is needed in order to clarify the effects of these agents on tumor cell biology and potential benefits of their use during cancer surgery.

Disclosures: There is no conflict of interest for all authors.

Acknowledgements: We thank to Serpil Demirag due to her contributes and comments and to Sylvia M. Bozdogan for her contributes in English editing.

Funding: The research received no specific grant from any funding agency in the public, commercial, or not-for-profit sectors.

Author’s contributions:
Erel Varlik K.:This author helped conduct the study and approved the final manuscript.
Yenisey Cigdem: This author helped conduct the study, analyze the data, correct the statistics, write the manuscript.
References

1. Johnson SM, Saint John BE, Dine AP. Local anesthetics as antimicrobial agents: a review. *Surg Infect (Larchmt)*. 2008; 9:205-13. https://doi.org/10.1089/sur.2007.036

2. Borgeat A, Aguierre J. Update on local anesthetics. *Curr Opin. Anaesthesiol*. 2010; 23:466-71. https://doi.org/10.1097/ACO.0b013e328339eef2

3. Cummings, K. C. 3rd, Xu, F., Cummings, L. C. & Cooper, G. S. A comparison of epidural analgesia and traditional pain management effects on survival and cancer recurrence after colectomy: a population-based study. *Anesthesiology*. 2012; 116:797-806. https://doi.org/10.1097/ALN.0b013e31824674f6

4. Exadaktylos, A. K., Buggy, D. J., Moriarity, D. C., Mascha, E. & Sessler, D. I. Can anesthetic technique for primary breast cancer surgery affect recurrence or metastasis? *Anesthesiology*. 2006; 105:660-664. https://doi.org/10.1097/00000542-200610000-00008

5. Biki, B. et al. Anesthetic technique for radical prostatectomy surgery affects cancer recurrence: a retrospective analysis. *Anesthesiology*. 2008; 109:180-187. https://doi.org/10.1097/ALN.0b013e318175f573

6. Snyder, G. L. & Greenberg, S. Effect of anesthetic technique and other perioperative factors on cancer recurrence. *Brit. J. Anaesth*. 2010; 105:106-115. https://doi.org/10.1093/bja/aep164

7. Sakaguchi, Masahiro, Yoshihiro Kuroda, and Munetaka Hirose. "The Antiproliferative Effect of Lidocaine on Human Tongue Cancer Cells with Inhibition of the Activity of Epidermal Growth Factor Receptor. *Anesthesia and Analgesia*. 2006; 102:1103-7. https://doi.org/12.1013/01.ane.0000198330.84341.35

8. Tavare, Aniket N, Nicholas J. S. Perry, Laura L. Benzonana, Masao Takata, and Daqing Ma. Cancer recurrence after surgery: direct and indirect effects of anesthetic agents. *Int J Cancer*. 2012; 125:137-50. https://doi.org/10.1002/ijc.26468

9. Jiang, Y, Hou H, Zhu J, Tian S, Yu L. Lidocaine inhibits the invasion and migration of TRPV6-expressing cancer cells by TRPV6 downregulation. *Oncology Letters*. 2016; 12:1164-1170. https://doi.org/10.3892/ol.2016.4709

10. Chang YC, Liu CL, Chen MJ, Hsu YW, Chen SN, Lin CH, Chen CM, Yang FM, Hu MC. Local anesthetics induce apoptosis in human breast tumor cells. *Anesth Analg*. 2011; 118:116-24. https://doi.org/10.1213/ANE.0b013e318294497

11. Nakamura K, Kido H, Morimoto Y, Morimoto H, Kobayashi S, Morikawa M, Hanjei T. Prilocaine induces apoptosis in osteoblastic cells. *Can J Anaesth*. 1999; 46:476-82. https://doi.org/10.1016/S0265-0215(99)70028-4

12. Werdehausen R, Fazeli S, Braun S, Hermanns H, Essmann F, Hollmann MW, Bauer I, Stevens MF. Apoptosis induction by different local anesthetics in a neuroblastoma cell line. *Br J Anaesth*. 2009; 103:711-8. https://doi.org/10.1093/bja/aep226

13. Perez-Castro R, Patel S, Garavito-Aguilar ZV, Rosenberg A, Recio-Pinto E, Zhang J, Blanck TJ, Xu F. Cytotoxicity of local anesthetics in human neuronal cells. *Anesth Analg*. 2009; 109:897-1007. https://doi.org/10.1213/ane.0b013e31819385e1

14. Chang YC, Liu CL, Chen MJ, Hsu YW, Chen SN, Lin CH, Chen CM, Yang FM, Hu MC. Local anesthetics induce apoptosis in human breast tumor cells. *Anesth Analg*. 2014; 118:116-24. https://doi.org/10.1213/ANE.0b013e318294497

15. Xuan W, Zhao H, Hankin J, Chen L, Yao S, Ma D. Local anesthetic bupivacaine induced ovarian and prostate cancer apoptotic cell death and underlying mechanisms in vitro. *Sci Rep*. 2016; 19(6):262-77. https://doi.org/10.1038/srep26277

16. Mammoto T, Higashiyama S, Mukai M, Higashiyama T, Hayashi Y, Kishi Y, Nakamura H, Akedo H. Infiltration anesthetic lidocaine inhibits cancer cell invasion by modulating ectodomain shedding of heparin-binding epidermal growth factor-like growth factor (HB-EGF). *J Cell Physiol*. 2002; 192:351-8. https://doi.org/10.1002/jcp.10145

17. Wang HW, Wang LY, Jiang L, Tian SM, Zhong TD, Fang XM. Amide-linked local anesthetics induce apoptosis in human non-small cell lung cancer. *J Thorac Dis*. 2016; 8:2748-2757. https://doi.org/10.21037/jtd.2016.09.66

18. Chang YC, Hsu YC, Liu CL, Huang SY, Hu MC, Cheng SP. Local anesthetics induce apoptosis in human thyroid cancer cells through the mitogen-activated protein kinase pathway. *PLoS One*. 2014; 21(9). https://doi.org/10.1371/journal.pone.0089563

19. Kawasaki C, Kawasaki T, Ogata M, Sato T, Chaudry IH. Lidocaine enhances apoptosis and suppresses mitochondrial functions of human neutrophil in vitro. *J Cell Physiol*. 2010; 68:401-8. https://doi.org/10.1002/jcp.10145

20. Kamiya Y, Ohta K, Kaneko Y, Nose T. Lidocaine-induced necrosis and apoptosis in U937 cells depending on its dosage. *Biomed Res*. 2005; 26:231-9. https://doi.org/10.2220/biomedres.26.231

21. Friederich P, Schmitz TP. Lidocaine-induced cell death in a human model of neuronal apoptosis. *Eur J Anaesthesiol*. 2002; 19:564-70. https://doi.org/10.1089/S0265205102000911

22. Werdehausen R, Braun S, Essmann F, Schulze-Osthoff K, Walczak H, Lipert F, Stevens MF. Lidocaine induces apoptosis via the mitochondrial pathway independently of death receptor signaling. *Anesthesiology*. 2007; 107:136-43. https://doi.org/10.1097/01.anes.0000268389.39436.66

23. Lee HT, Xu H, Siegel CD, Krichevsky IE. Local anesthetics induce human renal cell apoptosis. *Am J Nephrol*. 2003; 23:129-39. https://doi.org/10.1159/000069304

24. Hirata M, Sakaguchi M, Mochiida C, Sotozono C, Kageyama K, Ueda Y, Hirose M. Lidocaine inhibits tyrosine kinase activity of the epidermal growth factor receptor and suppresses proliferation of corneal epithelial cells. *Anesthesiology*. 2004; 100:1206-10. https://doi.org/10.1097/01.anes.00000542-200405000-00024